Literature DB >> 14582911

Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis.

D Miotto1, M P Ruggieri, P Boschetto, G Cavallesco, A Papi, I Bononi, C Piola, B Murer, L M Fabbri, C E Mapp.   

Abstract

The aim of this study was to determine whether the T-helper 2-type cytokines interleukin (IL)-13 and -4 are involved in mucus hypersecretion, the hallmark of chronic bronchitis (CB). Surgical specimens were examined from 33 subjects undergoing lung resection for localised peripheral malignant pulmonary lesions: 21 smokers with symptoms of CB, 10 asymptomatic smokers (AS) and two nonsmokers with normal lung function. The number of IL-4 and -13 positive (+) cells in the central airways was quantified. To better assess the cytokine profile, a count was also made of IL-5+ and interferon (IFN)-gamma+ cells. Compared to AS, the CB group had an increased number of IL-13+ and -4+ cells in the bronchial submucosa, while the number of IL-5+ and IFN-gamma+ cells were similar in all the groups. No significant associations were found between the number of cells expressing IL-13 or -4 and the number of inflammatory cells. Double labelling showed that 13.2 and 12.9% of IL-13+ cells were also CD8+ and CD4+, whereas 7.5 and 5% of IL-4+ cells were CD8+ and CD4+, respectively. In conclusion, T-helper-2 and -1 protein expression is present in the central airways of smokers and interleukin-4 and -13 could contribute to mucus hypersecretion in chronic bronchitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582911     DOI: 10.1183/09031936.03.00046402

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

1.  A novel technique to explore the functions of bronchial mucosal T cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity.

Authors:  M W Lethbridge; D M Kemeny; J C Ratoff; B J O'Connor; C M Hawrylowicz; C J Corrigan
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals.

Authors:  Jeffrey W Tyner; Edy Y Kim; Kyotaro Ide; Mark R Pelletier; William T Roswit; Jeffrey D Morton; John T Battaile; Anand C Patel; G Alexander Patterson; Mario Castro; Melanie S Spoor; Yingjian You; Steven L Brody; Michael J Holtzman
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

Review 3.  Immunogenetic programs for viral induction of mucous cell metaplasia.

Authors:  Michael J Holtzman; John T Battaile; Anand C Patel
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-16       Impact factor: 6.914

4.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.

Authors:  Bi Chen; Wen-Jie You; Shan Xue; Hui Qin; Xu-Ji Zhao; Miao Zhang; Xue-Qing Liu; Shu-Yang Zhu; Han-Dong Jiang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 6.  Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease.

Authors:  Hongwei Yao; Irfan Rahman
Journal:  Toxicol Appl Pharmacol       Date:  2011-02-04       Impact factor: 4.219

7.  Mucus in chronic airway diseases: sorting out the sticky details.

Authors:  Lauren Cohn
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

8.  Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease.

Authors:  B Barceló; J Pons; A Fuster; J Sauleda; A Noguera; J M Ferrer; A G N Agustí
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

9.  Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease.

Authors:  S Saha; V Mistry; R Siva; D Parker; R May; P Bradding; I D Pavord; C E Brightling
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

Review 10.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.